Ironwood Pharmaceuticals (IRWD) Set to Announce Earnings on Thursday

Ironwood Pharmaceuticals (NASDAQ:IRWD) is scheduled to post its quarterly earnings results before the market opens on Thursday, November 7th. Analysts expect Ironwood Pharmaceuticals to post earnings of $0.08 per share for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.

Ironwood Pharmaceuticals Trading Down 2.4 %

NASDAQ:IRWD opened at $4.15 on Thursday. Ironwood Pharmaceuticals has a twelve month low of $3.79 and a twelve month high of $15.70. The company has a market capitalization of $649.60 million, a P/E ratio of -0.61 and a beta of 0.48. The firm has a 50-day moving average price of $4.38 and a two-hundred day moving average price of $5.76.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on IRWD. StockNews.com upgraded Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, July 16th. Leerink Partnrs raised Ironwood Pharmaceuticals to a “hold” rating in a research note on Monday, September 9th. Leerink Partners started coverage on shares of Ironwood Pharmaceuticals in a research note on Monday, September 9th. They issued a “market perform” rating and a $5.00 target price for the company. Craig Hallum decreased their price target on shares of Ironwood Pharmaceuticals from $14.00 to $10.00 and set a “buy” rating on the stock in a research note on Friday, August 9th. Finally, Capital One Financial downgraded shares of Ironwood Pharmaceuticals from an “overweight” rating to an “equal weight” rating and lowered their price target for the stock from $12.00 to $4.00 in a report on Thursday, August 8th. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $12.17.

Insiders Place Their Bets

In other news, insider Minardo John sold 9,910 shares of the stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $4.27, for a total transaction of $42,315.70. Following the transaction, the insider now directly owns 284,661 shares in the company, valued at $1,215,502.47. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 12.90% of the stock is owned by corporate insiders.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.